Anticoagulation-free VV ECMO for Acute Respiratory Failure
Anticoagulation-free VV ECMO for Acute Respiratory Failure: A Pilot Safety and Feasibility Randomized Clinical Trial
Damian Ratano
40 participants
Sep 1, 2022
INTERVENTIONAL
Conditions
Summary
Currently international experts recommend therapeutic anticoagulation for veno-venous extracorporeal membrane oxygenation (VV-ECMO). Reports and case series suggest that the absence of therapeutic anticoagulation is safe for VV-ECMO. No randomized control trials have assessed this. The aim of this pilot study is to assess safety and feasibility of an "anticoagulation-free strategy" for veno-venous ECMO (VV-ECMO) in Acute respiratory distress syndrome (ARDS).
Eligibility
Inclusion Criteria1
- Adult patient with ARDS on VV-ECMO
Exclusion Criteria3
- Contraindication to anticoagulation with UFH (known heparin-induced thrombocytopenia, active hemorrhage, any surgery precluding the use of anticoagulation),
- Indication for therapeutic anticoagulation (pulmonary embolism or deep vein thrombosis, chronic anticoagulation therapy before ECMO insertion)
- Low-flow (\<2 liters/min) VV-ECMO (ECCO2R)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04273607